

# Hectd1 regulates intracellular localization and secretion of Hsp90 to control cellular behavior of the cranial mesenchyme

Anjali A. Sarkar and Irene E. Zohn

Center for Neuroscience Research, Children's Research Institute, Children's National Medical Center, Washington, DC 20010

**H**ectd1 mutant mouse embryos exhibit the neural tube defect exencephaly associated with abnormal cranial mesenchyme. Cellular rearrangements in cranial mesenchyme are essential during neurulation for elevation of the neural folds. Here we investigate the molecular basis of the abnormal behavior of *Hectd1* mutant cranial mesenchyme. We demonstrate that *Hectd1* is a functional ubiquitin ligase and that one of its substrates is Hsp90, a chaperone protein with both intra- and extra-cellular clients. Extracellular Hsp90 enhances migration of multiple cell types. In mutant cranial mesenchyme cells,

both secretion of Hsp90 and emigration of cells from cranial mesenchyme explants were enhanced. Importantly, we show that this enhanced emigration was highly dependent on the excess Hsp90 secreted from mutant cells. Together, our data set forth a model whereby increased secretion of Hsp90 in the cranial mesenchyme of *Hectd1* mutants is responsible, at least in part, for the altered organization and behavior of these cells and provides a potential molecular mechanism underlying the neural tube defect.

## Introduction

*Hectd1* mutant embryos show exencephaly (Zohn et al., 2007), a neural tube defect that occurs when the anterior neural tube fails to close completely during embryonic development. These congenital malformations represent some of the most common birth defects in humans (Zohn and Sarkar, 2008). Proper closure of the neural tube is dependent on the orchestration of several complex cellular processes in both the neural tissue and surrounding epithelium and mesenchyme (Copp et al., 2003; Copp, 2005). Importantly, elevation of the anterior neural folds is mediated by expansion of the extracellular matrix, which in turn results in increased spacing of the cells in the mesoderm-derived cranial mesenchyme (CM; Morriss and Solursh, 1978a,b; Schoenwolf and Fisher, 1983; Morris-Wiman and Brinkley, 1990a,b,c). Defects in expansion of the CM are associated with exencephaly in rodent models of neural tube defects. For example, treatment of rat embryos during neurulation with

hyaluronidase prevents expansion of the extracellular matrix, resulting in collapse of the CM and delayed neural tube closure (Morriss-Kay et al., 1986). Furthermore, exencephaly in *Twist* mutants is associated with reduced CM (Chen and Behringer, 1995), whereas we have shown that exencephaly in *Hectd1* mutant embryos is associated with denser mesoderm-derived CM (Zohn et al., 2007).

*Hectd1* encodes a novel homologous to E6-AP C-terminal (HECT)-domain containing E3 ubiquitin (Ub) ligase (Zohn et al., 2007). Ubiquitination involves a three-enzyme cascade (E1, E2, and E3), resulting in the conjugation of Ub as single (mono-ubiquitination; Ub) or multiple (multi- or polyubiquitination; Ub<sub>n</sub>) moieties onto either lysine (K) residues or the N terminus of substrate proteins (Pickart, 2001). The functional significance of Ub<sub>n</sub> is dependent on which K residues in Ub are used to form the chain. Conjugation onto K48 of Ub generally targets a substrate for proteasomal degradation, whereas K63-linked Ub chains regulate a multitude of processes including intracellular protein localization and trafficking (Mukhopadhyay and Riezman, 2007).

© 2012 Sarkar and Zohn. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

Correspondence to Irene E. Zohn: [izohn@cnmcresearch.org](mailto:izohn@cnmcresearch.org)

Abbreviations used in this paper: ALLN, *N*-acetyl-leucyl-leucyl-norleucinal; ANK, ankyrin domain; ARMS-PCR, amplification refractory mutation system PCR; CM, cranial mesenchyme; DMA, dimethyl amelioride; HECT, homologous to the E6-AP C terminus; *Hectd1*<sup>0</sup>, *Hectd1*<sup>openmind</sup>, *Hectd1*<sup>o</sup>, *Hectd1*<sup>wildtype</sup>; *Hectd1*<sup>X</sup>, *Hectd1*<sup>XC</sup>; HEK293T, human embryonic kidney 293; HMW, high molecular weight; Hsp, heat shock protein; Hsp90 $\alpha$ bd, Hsp90 $\alpha$  binding domain; LC-MS, liquid chromatography-mass spectrometry; mAb, monoclonal antibody; Ub, Ubiquitin; Ub<sub>n</sub>, polyubiquitin.

Heat shock proteins (Hsps) constitute a family of abundantly expressed protein chaperones that regulate numerous cellular functions, including protein folding and cell migration. Although the majority of studies on Hsp90 demonstrate intracellular functions, recent data establish that Hsp90 is secreted from the cell, stimulating enhanced motility (Eustace and Jay, 2004; Tsutsumi and Neckers, 2007). Although the full extent of extracellular client proteins remains unknown, Hsp90 is thought to exert its effect on cell motility in the extracellular space through its chaperone activity on cell surface receptors and extracellular matrix components (Tsutsumi and Neckers, 2007; Li et al., 2012). Furthermore, in spite of their clear importance in regulating migration outside the cell, our current understandings of the mechanisms controlling Hsp90 secretion remain fragmentary. Cell stressors such as treatment with proteasome inhibitors, heat shock, and hypoxia stimulate Hsp translocation to the membrane and/or secretion (Liao et al., 2000; Verschueren et al., 2002; Clayton et al., 2005; Li et al., 2007). Hsp90 does not have a signal sequence and is released from the cell in exosomes, secretory vesicles targeted for fusion with the plasma membrane (Hegmans et al., 2004; Cheng et al., 2008; McCready et al., 2010). Sorting of proteins into secretory vesicles is typically regulated by phosphorylation and/or ubiquitination (Bonifacino and Traub, 2003; Urbé, 2005). Accordingly, phosphorylation by protein kinase A (PKA) is required for both membrane translocation and secretion of Hsp90 (Wang et al., 2009). In contrast, the role of ubiquitination in Hsp90 secretion has not been explored.

Neural tube defects observed in *Hectd1* mutants illustrate its critical importance during embryonic development; however, the key substrates regulated by Hectd1 remain unknown. Our previous and present studies show that Hectd1 is important for the organization of the CM, which facilitates elevation of the cranial neural folds and neural tube closure (Zohn et al., 2007). Here we find, for the first time, that Hectd1 functions as a Ub ligase in vivo and binds to Hsp90, resulting in its K63-linked Ub<sub>n</sub>. We demonstrate that Hectd1-dependent Ub<sub>n</sub> of Hsp90 influences its intracellular localization and negatively regulates its secretion, as in the absence of Hectd1 Ub ligase activity, extracellular Hsp90 levels are increased. Furthermore, we show that the disorganized CM in *Hectd1* mutant embryos, a potential underlying cause of exencephaly, is due at least in part to the abnormal behavior of CM cells stimulated by the excess Hsp90 secreted from mutant cells.

## Results

### Exencephaly in *Hectd1* mutant embryos is associated with abnormal emigration of CM cells from explants

Our previous studies pointed to a failure of CM expansion as a potential underlying cause of exencephaly in *Hectd1* mutants (Fig. 1, A–F; also see Fig. 2 A for diagrams of *Hectd1* mutant alleles used in this study; Zohn et al., 2007). In addition to the increased cell density of mesoderm-derived CM cells in *Hectd1* mutants previously noted (Zohn et al., 2007), *Hectd1* mutant CM cells exhibit an altered morphology when compared with


control cells (Fig. 1, E and F). *Hectd1* mutant CM cells appeared larger than in wild-type CM. To quantitate these differences, cell area (Fig. 1 G) and cell perimeter were measured in hematoxylin and eosin-stained CM sections of embryonic day 9.5 (E9.5) wild-type and *Hectd1* mutant embryos, and these values were used to calculate a shape coefficient (Fig. 1 H). These analyses revealed that CM cells in *Hectd1*<sup>openmind</sup> (*Hectd1*<sup>O</sup>) mutants are larger and have a significantly different shape in *Hectd1*<sup>wildtype</sup> (*Hectd1*<sup>W</sup>) embryos (Fig. 1, E–H).

Mesoderm-derived CM cells are not generally considered a migratory population of cells. Rather, elevation of the neural folds is thought to be driven by the expansion of the extracellular matrix, displacing CM cells and leading to increases in the space between individual cells of the CM (Morris and Solursh, 1978a,b; Schoenwolf and Fisher, 1983; Morris-Wiman and Brinkley, 1990a,b,c). Nevertheless, we have found that cells will migrate from CM explants when cultured on fibronectin-coated plates. To establish that the aberrant morphology observed in the CM of *Hectd1* mutant embryos represents altered behavior of mutant cells, we performed a CM explant outgrowth assay. For these experiments, CM explants from E8.5 wild-type and *Hectd1*<sup>O</sup> embryos were microdissected and cultured on fibronectin-coated plates. We chose fibronectin as a substrate, as it is commonly used in these types of outgrowth assays, is generally associated with cell migration during embryonic development, and is a component of the extracellular matrix in the CM (Tuckett and Morris-Kay, 1986; Zohn et al., 2006). Analyses of the mean number of cells emigrating from the explants demonstrated that *Hectd1*<sup>O</sup> mutant CM cells emerge from the explant at a significantly ( $P < 0.05$ ) higher rate than wild-type cells (Fig. 1, I–L and N). In addition, *Hectd1*<sup>O</sup> mutant CM cells migrated significantly ( $P < 0.05$ ) further from the explant than wild-type cells (Fig. 1 M). Differences in emigration of *Hectd1*<sup>O</sup> mutant cells could reflect differences in proliferation or death in the CM; however, our previous results indicate that these are not altered in *Hectd1* mutant CM (Zohn et al., 2007). Alternatively, differences in emigration from the explant could indicate that *Hectd1*<sup>O</sup> mutant cells are differentially recruited from the explant than wild-type cells. Additionally, the observation that *Hectd1*<sup>O</sup> mutant cells migrated further suggests that mutant cells are likely more motile than their wild-type counterparts. In conclusion, these results demonstrate that the cells in *Hectd1*<sup>O</sup> mutant CM exhibit abnormal behaviors.

### *Hectd1* encodes a functional Ub ligase

A gene trap insertion disrupting the HECT domain of Hectd1 in the *Hectd1*<sup>XC</sup> (*Hectd1*<sup>X</sup>) allele phenocopies defects observed in *Hectd1*<sup>O</sup>-null mutants (Zohn et al., 2007), which indicates that the HECT domain is necessary for the biological activity of Hectd1. To establish that Hectd1 is a functional E3 Ub ligase, full-length HA-tagged constructs encoding wild-type Hectd1 (pCMV-HA-Hectd1) or a ligase incompetent version of Hectd1 (pCMV-HA-Hectd1\*), in which the conserved active site cysteine<sup>2579</sup> is mutated to glycine (Fig. 2 A), were transfected into human embryonic kidney 293T (HEK293T) cells.

To assess the effect of the proteasome on the stability of proteins ubiquitinated by Hectd1, cultures were treated for




**Figure 1. Exencephaly is associated with altered behavior of CM cells in *Hectd1* mutant embryos during neurulation.** (A and B) *Hectd1*<sup>W</sup> (A) and exencephalic *Hectd1*<sup>O</sup> (B) embryos at E9.5. (C–F) Hematoxylin and eosin (H&E) staining of transverse sections of E9.5 embryo heads taken at the level of the yellow broken lines in A and B revealing increased density and altered cell morphology of the CM in *Hectd1*<sup>O</sup> (D and F) compared with the *Hectd1*<sup>W</sup> (C and E) heads. E and F show higher magnification images of the boxes in C and D. Insets in E and F represent high-magnification images of individual cells. (G and H) Morphometric measurements reveal that *Hectd1*<sup>O</sup> mutant CM cells are larger and have a different shape coefficient than *Hectd1*<sup>W</sup> cells ( $n = 130$  cells). (I–N) The mean migratory distance (M) from the circumference of the explant (broken lines) to the migratory front and the mean cell number (N) in a square area ( $200 \mu\text{m}^2$ , box in I and J) perpendicular and mid-distant between the migratory front and explant circumference are increased in *Hectd1*<sup>O</sup> (J) compared with *Hectd1*<sup>W</sup> (I) CM explants. Error bars represent the mean  $\pm$  SEM (SEM) of five independent experiments performed in triplicate. The shapes of cells migrating on fibronectin away from the explant do not appear to differ between *Hectd1*<sup>O</sup> (L) and *Hectd1*<sup>W</sup> (K). All data are representative of three independent experiments unless otherwise indicated. W, *Hectd1*<sup>W</sup>; O, *Hectd1*<sup>O</sup>. Bars: (B) 300  $\mu\text{m}$ ; (D) 125  $\mu\text{m}$ ; (F) 50  $\mu\text{m}$ ; (I and J) 200  $\mu\text{m}$ ; (K and L) 20  $\mu\text{m}$ .

4 h before lysis with the cell-permeable proteasomal inhibitor MG132 (carbobenzoxy-leucyl-leucyl-leucinal). Western blots of Hectd1-immunoprecipitated lysates were probed with anti-Ub antibodies, revealing that cells expressing HA-Hectd1 contain significantly more Ub-conjugated proteins bound to Hectd1 than cells expressing cysteine mutant HA-Hectd1\* (Fig. 2 B). These results demonstrate that Hectd1 exhibits Ub ligase activity. Furthermore, because Ub proteins are not stabilized by proteasomal inhibition, Hectd1 substrates are likely not targeted for proteasomal degradation.

We also examined the Ub ligase activity of Hectd1 in vivo (Fig. 2, C and D). For these experiments, we took advantage of our two mutant mouse lines (Fig. 2 A; Zohn et al., 2007). The *Hectd1*<sup>O</sup> allele contains a nonsense mutation resulting in truncation of Hectd1, whereas the *Hectd1*<sup>X</sup> allele contains a gene trap insertion disrupting the catalytic HECT domain but leaving the

substrate interaction domains intact. Furthermore, wild-type (*Hectd1*<sup>W</sup>) and *Hectd1*<sup>X</sup> proteins but not *Hectd1*<sup>O</sup> were detected by our anti-Hectd1 antibody, demonstrating antibody specificity (Fig. 2, A and C; and Fig. S1). The presence of both native and high molecular weight (HMW) Hectd1 in immunoprecipitates of Hectd1 from *Hectd1*<sup>W</sup> but not *Hectd1*<sup>O</sup> E11.5 embryo head lysates confirms antibody specificity and that the HMW band is Hectd1 (Fig. 2 C). Significantly, this HMW band is not detected in *Hectd1*<sup>X</sup> mutant lysates, where the Ub ligase domain of Hectd1 is disrupted, indicating that the HMW band represents Hectd1 auto-ubiquitination (Fig. 2 C). Additionally, Hectd1 incorporates K63-linked Ub<sub>n</sub> chains in vivo that are absent in *Hectd1*<sup>X</sup> mutant CM cells (Fig. 2 D). Because conjugation of K63-linked Ub<sub>n</sub> chains onto substrate proteins generally serves nonproteolytic functions, this result further suggests that Hectd1-dependent Ub<sub>n</sub> is unlikely to target substrates to the proteasome for degradation.

**Figure 2. Hectd1 functions as a Ub ligase.** (A) Diagrammatic sketch of the *Hectd1* alleles and plasmid constructs used in this study: *Hectd1<sup>W</sup>* (W; wild type), *Hectd1<sup>O</sup>* (O; *opm*; openmind), and *Hectd1<sup>X</sup>* (X; XC gene trap) are mouse alleles; Myc-Hectd1<sup>ANK</sup>, HA-Hectd1, and HA-Hectd1\* are mammalian expression constructs. *Hectd1<sup>O</sup>* was generated in an ENU mutagenesis screen and harbors a missense mutation resulting in truncation of Hectd1. *Hectd1<sup>X</sup>* is a gene trap allele where the Ub ligase domain is disrupted by insertion of a β-geo (LacZ) cassette (Zohn et al., 2007). HA-Hectd1<sup>ANK</sup> consists of amino acids 1–551 of Hectd1 encompassing the ankyrin (ANK) domain. pCMVHA-Hectd1\* is Ub ligase deficient because of mutation of the active site cysteine (C2579G). Other motifs present in Hectd1 include Mindbomb (mib) and Sad1/UNC (SUN) domains. The inverted Y denotes the paratope of the Hectd1 antibody that recognizes *Hectd1<sup>W</sup>* and *Hectd1<sup>X</sup>* but not *Hectd1<sup>O</sup>* proteins. (B) Reduced ubiquitination of Hectd1 and associated proteins in HEK293T cells expressing cysteine mutant Hectd1\*. HA-Hectd1 immunoprecipitates were subjected to Western blot analyses to detect Hectd1 and mono- and polyubiquitylated protein conjugates (FK2). (C) The appearance of HMW Hectd1 is dependent on its ligase activity in vivo. Hectd1 immunoprecipitates from E11.5 embryo heads of the indicated genotypes were probed with anti-Hectd1 antibody. (D) The conjugation of K63-linked Ub chains onto Hectd1 is dependent on its ligase activity. Hectd1 was immunoprecipitated from *Hectd1<sup>W</sup>* and *Hectd1<sup>X</sup>* CM cultures and immunoblotted with antibodies to detect K63-linked Ub chains (K63Ub) and Hectd1. (E and F) Reduction of total Ub proteins in *Hectd1<sup>X</sup>* compared with *Hectd1<sup>W</sup>* CM cultures. (E) Ub proteins were pulled down (PD) using Rad23 beads followed by immunoblotting to detect mono- and polyubiquitylated protein conjugates (FK2). (F) Quantitation of normalized intensity of Western blots shown in E. Error bars represent the mean ± SEM of two independent experiments performed in triplicate. Statistical significance was determined by paired two-tailed Student's *t* tests. W, *Hectd1<sup>+/+</sup>*; O, *Hectd1<sup>opm/opm</sup>*; X, *Hectd1<sup>XX</sup>*; WCL, whole cell lysate; Con, control; IB, immunoblot; IP, immunoprecipitation; FK2, anti-mono- and polyubiquitylated proteins; (Ub)<sub>n</sub>, Ub<sub>n</sub>; K63Ub, lysine 63 linked Ub<sub>n</sub> chains.



### Loss of Hectd1 affects the global cellular Ub protein pool

To determine the extent of cellular ubiquitination influenced by Hectd1, Ub proteins were enriched from lysates of CM cultures isolated from the cranial region of E12.5 *Hectd1<sup>W</sup>* and *Hectd1<sup>X</sup>* mutant embryos. To enrich for Ub proteins, cell lysates were incubated with the Ub-binding protein Rad23 bound to agarose beads (Chen and Madura, 2002; Hartmann-Petersen and Gordon, 2004). Western blotting of enriched proteins reveals a reduction in the total amount of Ub proteins in mutant samples (Fig. 2, E and F). These results indicate that Hectd1 likely catalyzes the ubiquitination of multiple and/or highly abundant proteins.


### Identification of Hsp90 $\alpha$ as a candidate Hectd1 substrate

HECT domain E3 Ub ligases physically interact with their substrates. To elucidate the pathways regulated by Hectd1, we conducted two independent proteomic screens to identify Hectd1 interactors and identified Hsp90 in both screens. We initially


performed a yeast two-hybrid screen using the N-terminal 551 amino acids of Hectd1 containing the ankyrin domain (Hectd1<sup>ANK</sup>; Fig. 2 A) as bait to screen an E11.5 mouse cDNA library. Out of 4.5 million clones screened, 23 unique clones were identified, including two identical clones encompassing amino acids 241–459 of Hsp90 $\alpha$  (Hsp90 $\alpha$  binding domain [Hsp90 $\alpha$ bd]). This region includes the charged domain 1 (CD1, amino acids 237–271) and ATPase domain (272–617), and is highly homologous to Hsp90 $\beta$  in primary amino acid sequence (red bar in Fig. 3 A). The second approach used liquid chromatography–mass spectrometry (LC-MS) to screen for proteins that coimmunoprecipitated with endogenous full-length Hectd1 from E12.5 mouse embryo heads. From this screen, seven peptide fragments of Hsp90 were found (dots in Fig. 3 A and Fig. 3, B and C). Identification of Hsp90 in both proteomic screens suggested that members of the Hsp90 superfamily may be substrates of Hectd1.

### Hectd1 and Hsp90 $\alpha$ physically interact

To explore the interaction between Hectd1 and Hsp90 (the Hsp90 $\alpha$  isoform was used in all assays), we performed a series



**Figure 3. Hectd1 physically interacts with Hsp90 $\alpha$ .** (A) Yeast two-hybrid screening of an E11.5 embryonic mouse cDNA library using Hectd1<sup>ANK</sup> as bait detected Hsp90 $\alpha$  (Gene ID: Hsp90aa1). Two identical clones of Hsp90 $\alpha$  consisting of amino acids 241–459 (Hsp90 $\alpha$ bd) of the 732-amino acid Hsp90 $\alpha$  protein partially overlap with the first charged domain (CD1, amino acids 236–272) and the ATPase domain (amino acids 272–618) of Hsp90 $\alpha$ . Black dots indicate locations of Hsp90 peptide fragments found by LC-MS analysis: NPDDITQEYGYEFYK (300–315), TLTIVDTGIGMTK (88–100), KAD-LINNLGTIAKS (100–113), and GVVVSEDLPLNISR (387–400). Peptides common to Hsp90 $\beta$  include: KEDQTEYLEERR (190–201), RDNSTMGYMMAMK (620–632), and YIDQEELNKK (284–292). The C-terminal amino acid sequence MEEVD of Hsp90 $\alpha$  is essential for regulated secretion. (B and C) Liquid chromatography and tandem mass spectrometry (LC-MS/MS) proteomic screening of Hectd1-binding proteins from E10.5 Hectd1<sup>W</sup> embryo head lysates. Hectd1 was immunoprecipitated and associated proteins were resolved by 3–8% Tris-Acetate SDS-PAGE and visualized by Coomassie staining. (B) Individual bands from the Coomassie-stained gel were subjected to tryptic proteolysis, and the resulting peptides were analyzed by LC-MS/MS. (C) Representative MS/MS of a 1,293.54 D peptide. This and six other peptides (dots in A) with high XC scores (3.3–3.7) were identified as belonging to Hsp90 $\alpha$  and Hsp90 $\beta$  when searched against the mouse Uniprot protein database using the Sequest algorithm as diagrammed in A. (D) Hsp90 $\alpha$ bd binds to Hectd1<sup>ANK</sup> in rabbit reticulocyte lysates. In vitro translated, biotinylated Hsp90 $\alpha$ bd and Hectd1<sup>ANK</sup> were bound and immunoprecipitated using the indicated antibodies and detected by Western blotting with streptavidin-HRP. (E and F) Hectd1 binds to Hsp90 in HEK293T cells. Cells were transfected and immunoprecipitated proteins were subjected to Western blot analyses as indicated. (E) Hsp90 $\alpha$ bd binds to Hectd1<sup>ANK</sup> in HEK293T cells. (F) Full-length Hsp90 and Hectd1 bind in HEK293T cells. (G) Hsp90 binds to Hectd1 in the developing embryo. Hectd1 was immunoprecipitated from lysates prepared from E12.5 Hectd1<sup>W</sup> and Hectd1<sup>O</sup> embryo heads and subjected to Western blot analysis as indicated ( $n = 4$ ). (H and I) Hsp90 binds to Hectd1 but not the related HECT domain containing Nedd4 Ub ligase. (H and I) HEK293T cells were transfected with HA-Nedd4 or HA-Hectd1 along with Myc-Hsp90. They were then HA immunoprecipitated and subjected to Western blotting (H), or Hsp90 (I) was immunoprecipitated from E12.5 Hectd1<sup>W</sup> and Hectd1<sup>O</sup> embryo head lysates followed by Western blotting to detect Nedd4 and Hectd1. All data are representative of three independent experiments unless otherwise indicated. W, Hectd1<sup>+/+</sup>; O, Hectd1<sup>opm/opm</sup>; X, Hectd1<sup>X/X</sup>; WCL, whole cell lysate; IB, immunoblot; IP, immunoprecipitation.



**Figure 4. Hectd1 is required for K63-linked Ub<sub>n</sub> of Hsp90.** (A–D) HEK293T cells were transfected, and lysates were subjected to immunoprecipitation and Western blot analysis as indicated. (A) Ubiquitination of Myc-Hsp90 increases with expression of HA-Hectd1 ( $n = 2$ ). (B) siRNA-mediated knockdown of endogenous Hectd1 reduces the accumulation of HMW-Hsp90 $\alpha$  ( $n = 2$ ). (C) Hsp90 $\alpha$  ubiquitination utilizes K63 linkages. (D) Hectd1-dependent polyubiquitination of Hsp90 occurs primarily through K63 linkages. (E) HMW Hsp90 species are reduced in *Hectd1* mutant heads. E12.5 *Hectd1*<sup>W</sup> (W) and *Hectd1*<sup>X</sup> (X) embryos were cultured in the presence of 10  $\mu$ M MG132 for 3 h before lysis and immunoprecipitation of Hectd1. Immunoprecipitates were subjected to Western blot analyses to detect Hsp90 that coimmunoprecipitated with Hectd1. (F) Hsp90 ubiquitination is reduced in CM cultures from *Hectd1*<sup>0</sup> (O) and *Hectd1*<sup>X</sup> (X) mutants compared with *Hectd1*<sup>W</sup> (W). Hsp90 was immunoprecipitated from E12.5 CM primary cultures in highly denaturing ubiquitination buffer plus 5% SDS and subjected to Western blot analyses as indicated. The appearance of a 30-kD ubiquitinated protein (asterisk) is reduced in *Hectd1* mutant cells. All data are representative of three independent experiments unless otherwise indicated. Abbreviations: W, *Hectd1*<sup>+/+</sup>; O, *Hectd1*<sup>0pm/0pm</sup>; X, *Hectd1*<sup>XX</sup>; WCL, whole cell lysate; IB, immunoblot; IP, immunoprecipitation; (Ub)<sub>n</sub>, Ub<sub>n</sub>; wt-Ub, wild-type Ub; K48R, mutant Ub lysine 48 arginine; K63R, mutant Ub lysine 48 arginine; K0, lysineless Ub.


of in vitro and in vivo binding assays. Myc-Hectd1<sup>ANK</sup> and HA-Hsp90 $\alpha$ bd (the fragment identified in the yeast two-hybrid screen) bind in an in vitro binding assay (Fig. 3 D) and when coexpressed in HEK293T cells (Fig. 3 E). Additionally, in HEK293T cells, full-length Myc-Hsp90 binds to both full-length wild-type

Hectd1 (HA-Hectd1) and cysteine mutant Hectd1 (HA-Hectd1\*; Figs. 2 A and 3 F). Furthermore, immunofluorescence analyses reveal that Myc-Hsp90 and HA-Hectd1 extensively colocalize when expressed in HEK293T cells (Fig. S2). Significantly, binding of endogenous proteins was detected in E12.5 head lysates from *Hectd1*<sup>W</sup> but not *Hectd1*<sup>0</sup> mutant embryos (Fig. 3 G). Intriguingly, binding was detected between endogenous Hsp90 and Hectd1 in the developing embryo under much more stringent conditions (e.g., radioimmunoprecipitation assay buffer vs. immunoprecipitation buffer with 0.1% Triton X-100; see Materials and methods) than when expressed in cell lines, which indicates that other factors likely facilitate this interaction in vivo. Importantly, demonstrating the specificity of binding in our assay conditions, Hectd1 but not Nedd4 (neural precursor cell expressed developmentally down-regulated protein 4), a related HECT domain Ub ligase, coimmunoprecipitated with Hsp90 in transfected HEK293T cells and head lysates from E12.5 *Hectd1*<sup>W</sup> and *Hectd1*<sup>X</sup> mutant embryos (Fig. 3, H and I).

#### Hectd1 is required for K63-linked Ub<sub>n</sub> of Hsp90

Next we tested whether the interaction of Hectd1 with Hsp90 $\alpha$  results in the ubiquitination of Hsp90. Hsp90 coexpressed with Hectd1 in HEK293T cells resulted in the appearance of HMW Ub-Hsp90 species (Fig. 4 A). Furthermore, siRNA-mediated knockdown of Hectd1 in HEK293T cells reduced the appearance of HMW Myc-Hsp90 (Fig. 4 B). To discern the Ub<sub>n</sub> chain linkage specificity on Hsp90, HEK293T cells were transfected with Myc-Hsp90 along with wild-type Ub or Ub constructs where the critical lysine residues K48 or K63 were mutated to arginine (K48R-Ub and K63R-Ub, respectively). These mutant Ub proteins will incorporate into growing Ub chains, but if the mutated residue is utilized for chain elongation, the chain will fail to extend. In addition, a mutant Ub construct where all lysines in Ub are mutated to arginine (K0-Ub) was used as a negative control for chain elongation. Wild-type and K48R-Ub incorporated, whereas K0-Ub and K63R-Ub failed to incorporate into the Ub<sub>n</sub> chains on Hsp90 (Fig. 4 C). This result indicates that Ub<sub>n</sub> on Hsp90 utilizes K63 linkages. Similarly, incorporation of K63-Ub<sub>n</sub> is increased in HEK293T cells transfected with HA-Hectd1 but not ligase-deficient HA-Hectd1\* (Fig. 2 D). Together, these observations indicate that the Hectd1-dependent appearance of HMW Hsp90 species is primarily caused by addition of K63 linkages.

To determine the in vivo relevance of Hectd1-dependent Hsp90 ubiquitination, we tested whether mutation of Hectd1 in the embryo would have an effect on endogenous Ub<sub>n</sub>-Hsp90 levels. To ensure stabilization of Ub<sub>n</sub>-protein conjugates in the embryo, we devised a short-term embryo culture protocol in the presence of the well-characterized cell-permeable proteasome inhibitor MG132. To determine if Hectd1 influences Ub<sub>n</sub> of Hsp90 in vivo, E11.5 wild-type (*Hectd1*<sup>W</sup>) and mutant (*Hectd1*<sup>X</sup>) embryos were cultured in the presence of MG132, followed by immunoprecipitation of Hectd1 and Western blotting to detect Hsp90. The gene trap insertion in *Hectd1*<sup>X</sup> disrupts the catalytic HECT domain but leaves the substrate interaction domains (Zohn et al., 2007) and the epitope recognized by our anti-Hectd1




**Figure 5. *Hectd1* affects Hsp90 localization and secretion.** (A and B) *Hectd1* Ub ligase activity is required for normal cytoplasmic distribution of Hsp90. (A–D) *Hectd1<sup>W</sup>* (A and C) and *Hectd1<sup>X</sup>* (B and D) CM cells were subjected to immunofluorescence analyses to detect total Hsp90 (A and B) or extracellular Hsp90 (C and D). Arrows indicate membrane-concentrated Hsp90 (B) or extracellular Hsp90 (D). (E–J) *Hectd1*-dependent ubiquitination prevents ALLN-induced translocation of Hsp90 to the membrane. HEK293T cells transfected as indicated were treated (H–J) or not treated (E–G) with ALLN and immunostained to detect Myc-Hsp90. Arrows indicate membrane-concentrated Hsp90. (K) Mutation of *Hectd1* results in increased secretion of Hsp90. ELISA was used to detect Hsp90α in conditioned media from *Hectd1<sup>W</sup>*, *Hectd1<sup>O</sup>*, and *Hectd1<sup>X</sup>* CM cultures. (L) Expression of HA-Hectd1 but not Ub ligase-deficient HA-Hectd1\* reduced secretion of Hsp90 in HEK293T cells. Statistical significance was determined by paired two-tailed Student's *t* tests. Error bars represent the mean  $\pm$  SEM (SEM) of three independent experiments performed in triplicate. (M–N') Hsp90 (M and N) colocalizes (M' and N') with LAMP2 (M' and N') in the membrane (arrows) of *Hectd1<sup>O</sup>* CM cells. All data are representative of three independent experiments unless otherwise indicated. W, *Hectd1<sup>+/+</sup>*; O, *Hectd1<sup>opm/opm</sup>*; X, *Hectd1<sup>X/X</sup>*. Bars, 10  $\mu$ m.

antibody intact (Fig. 2 A). In *Hectd1<sup>W</sup>* lysates, HMW Hsp90 that coimmunoprecipitated with *Hectd1* is detected as multiple bands (Fig. 4 E); however, in *Hectd1<sup>X</sup>* mutant lysates, HMW Hsp90 species are markedly diminished with a corresponding increase in low molecular weight Hsp90. Similarly, immunoprecipitation of Hsp90 from *Hectd1<sup>W</sup>*, *Hectd1<sup>X</sup>*, or *Hectd1<sup>O</sup>* primary CM cultures in a highly denaturing ubiquitination lysis buffer plus 5% SDS to minimize interaction of associated proteins demonstrates reduced ubiquitination of Hsp90 in *Hectd1* mutant CM cells (Fig. 4 F). Interestingly, coimmunoprecipitation of Hsp90 with a 30kD Ub<sub>n</sub>-protein is dependent on *Hectd1* activity (Fig. 4 F, asterisk). The binding of Hsp90 to this protein in highly denaturing conditions indicates a tight association or possibly a proteolytically processed Hsp90 fragment.

#### ***Hectd1*-dependent Ub<sub>n</sub> influences the cellular localization and secretion of Hsp90**

The conjugation of K63-linked Ub<sub>n</sub> chains onto substrate proteins typically does not target them to the proteasome for degradation

but rather influences other processes such as intracellular localization/trafficking (Mukhopadhyay and Riezman, 2007). To determine if *Hectd1*-dependent K63-linked Ub<sub>n</sub> of Hsp90 regulates its intracellular localization, we examined the distribution of Hsp90 in primary CM cultures prepared from E10.5 *Hectd1<sup>W</sup>* and *Hectd1<sup>X</sup>* embryo heads. In *Hectd1<sup>W</sup>* CM cultures, Hsp90 is localized in the cytoplasm as well as in the nucleus (Fig. 5 A). In contrast, in *Hectd1<sup>X</sup>* mutant cells, Hsp90 was concentrated at the plasma membrane in ruffled-like structures (Fig. 5 B, arrows). To further investigate the plasma membrane localization of Hsp90, cells were immunostained with the primary anti-Hsp90 antibody before permeabilization with Triton X-100 to visualize only the Hsp90 localized to the outside of the plasma membrane. This experiment revealed extracellular localization of Hsp90 in *Hectd1<sup>O</sup>* mutant but not *Hectd1<sup>W</sup>* CM cells (Fig. 5, C and D). In addition, we used an experimental paradigm to stimulate Hsp90 translocation to the membrane by treating HEK293T cells with proteasomal inhibitors (Verschueren et al., 2002) to examine the role of *Hectd1* in controlling the intracellular localization of



**Figure 6. Abnormal emigration of *Hectd1* mutant CM from explants is highly dependent on Hsp90 activity.** (A–D) CM explants were cultured in the presence (B) or absence (A) of 100 ng/ml Hsp90 protein. Migratory distance (C) and cell numbers (D) are increased in Hsp90-treated explants ( $n = 3$ ). (E–N) CM explants from *Hectd1<sup>W</sup>* (E, F, J, and K) and *Hectd1<sup>O</sup>* (G, H, L, and M) embryos were incubated with DMSO/vehicle (E, G, J, and L), 25  $\mu$ g/ml anti-Hsp90 antibody (F and H), or 200  $\mu$ M DMA (K and M). The broken lines denote the edge of the explant (E) and the migration front. Insets show enlarged views of cells migrating from the explant. (I and N) Mean distance of cells migrated from explants treated in E–H and J–M, respectively. Error bars represent the mean  $\pm$  SE of five independent experiments (unless otherwise indicated) performed in triplicate. Bar, 200  $\mu$ m.

Downloaded from <http://jcb.rupress.org/jcb/article/196/6/789/1752843.pdf> by guest on 08 February 2020

Hsp90. Myc-Hsp90 is localized to the cytoplasm in HEK293T cells cotransfected with either HA-Hectd1 or HA-Hectd1\* (Fig. 5, E–G). Treatment with the proteasomal inhibitor *N*-acetyl-leucyl-leucyl-norleucinal (ALLN; Fig. 5 H–J) results in Myc-Hsp90 localized to the membrane in cells transfected with Myc-Hsp90 alone or cotransfected with ligase-incompetent HA-Hectd1\*. In contrast, cotransfection with HA-Hectd1 results in primarily cytosolic Myc-Hsp90.

Plasma membrane localization of Hsp90 has been associated with secretion of Hsp chaperones through the exosome pathway (Hegmans et al., 2004; Cheng et al., 2008; McCready et al., 2010). Indeed, in *Hectd1<sup>O</sup>* mutant but not *Hectd1<sup>W</sup>* cells, Hsp90 colocalized extensively with LAMP2 (lysosomal-associated membrane protein 2), a protein that shuttles between lysosomes, endosomes, and the plasma membrane—organelles involved in exosomal secretion of Hsp90 (Fig. 5, M and N). Importantly, Hsp90 secretion is significantly ( $P < 0.05$ ) increased in *Hectd1<sup>X</sup>* and *Hectd1<sup>O</sup>* mutants compared with *Hectd1<sup>W</sup>* CM cells as quantified by a sensitive ELISA assay of Hsp90 protein in the conditioned media of *Hectd1<sup>X</sup>*, *Hectd1<sup>O</sup>*, and *Hectd1<sup>W</sup>*

CM cells (Fig. 5 K). Conversely, Hsp90 secretion was reduced in HEK293T cells cotransfected with Myc-Hsp90 along with HA-Hectd1 but not HA-Hectd1\* (Fig. 5 L). Together, these results demonstrate that Hectd1-dependent Ub<sub>n</sub> of Hsp90 targets it away from the membrane and the secretory pathway.

#### Enhanced migration of *Hectd1* mutant CM cells is associated with increased Hsp90 secretion

Secreted Hsp90 can enhance cell migration in numerous experimental paradigms (Tsutsumi and Neckers, 2007). Therefore, our observations that Hectd1 regulates Hsp90 secretion and that in *Hectd1* mutant CM cells Hsp90 secretion is increased suggest a potential molecular mechanism underlying the abnormal behavior of mutant CM cells (Fig. 1). To establish that Hsp90 can stimulate emigration and migration of cells from CM explants, CM explants from wild-type embryos were microdissected, plated on fibronectin-coated plates, and incubated with recombinant Hsp90 protein. Treatment with Hsp90 significantly increased ( $P < 0.05$ ) both the


cells emigrating from the explants and the distance migrated (Fig. 6, A–D), which demonstrates that increased extracellular Hsp90 would be sufficient to cause the abnormal behavior of *Hectd1* mutant CM cells in this assay. Furthermore, migration of *Hectd1*<sup>0</sup> mutant CM cells is highly dependent on secreted Hsp90. Treatment of *Hectd1*<sup>W</sup> and *Hectd1*<sup>0</sup> explants with a dose of anti-Hsp90 antibody that does not affect emigration of CM cells from *Hectd1*<sup>W</sup> explants significantly inhibited emigration of cells from *Hectd1*<sup>0</sup> mutant explants (Fig. 6, E–I). Similarly, treatment of explants with dimethyl amiloride (DMA), an inhibitor of secretion, reduced emigration of CM cells from *Hectd1*<sup>0</sup> mutant explants (Fig. 6, J–N). Together, these data demonstrate that enhanced emigration and migration of *Hectd1* mutant CM cell explants is at least partly caused by increased secretion of Hsp90 in the absence of Hectd1 ubiquitination activity.

## Discussion

Here we demonstrate that Hectd1 is a functional Ub ligase and that Hectd1-dependent ubiquitination plays an essential role in controlling Hsp90 secretion by negatively regulating secretion of Hsp90. Our data indicate that Hectd1 binds to Hsp90 and is required for conjugation of K63-linked Ub<sub>n</sub> chains onto this cellular chaperone. Fig. 7 summarizes a model of how mutation of Hectd1 results in alterations in CM behavior that have emerged from this study. In the absence of Hectd1 Ub ligase activity, Hsp90 becomes concentrated at the cell surface of CM cells rather than its normal cytoplasmic distribution. Additionally, Hsp90 secretion is increased in *Hectd1* mutant CM cells. This excessive secretion is at least partially responsible for the abnormal behavior of *Hectd1* mutant CM cells. We propose that this abnormal CM behavior contributes to the failure of CM expansion found in *Hectd1* mutant embryos. Because this CM defect is associated with failure of neural fold elevation (Fig. 1; Zohn et al., 2007), these results raise the distinct possibility that Hsp90 may be a critical Hectd1 substrate and that failure to regulate Hsp90 secretion in *Hectd1* mutant CM may contribute to exencephaly in *Hectd1* mutants.

### Hectd1-dependent ubiquitination of Hsp90

Hsps have been shown to interact with other E3 Ub ligases, although a direct role in ubiquitination of these chaperones has not been demonstrated. The U-box E3 ligase, C terminus of Hsc70-interacting protein (CHIP) interacts with Hsp90, Hsp70, and Hsp40; however, instead of ubiquitinating these, CHIP acts as a quality controller by selectively targeting associated client proteins for degradation (McDonough and Patterson, 2003; Murata et al., 2003). In contrast, our data demonstrate that Hectd1 is required for K63-Ub<sub>n</sub> of Hsp90 $\alpha$  itself, raising the possibility that Hectd1-dependent ubiquitination of Hsp90 $\alpha$  serves an alternate purpose beyond that of quality control of client proteins. Although our data do not rule out the distinct possibility that Hectd1 also regulates the selective ubiquitination of Hsp90 client proteins, in this study we restricted ourselves to examining the Ub conjugation and



**Figure 7. Proposed model depicting consequences of Hectd1-mediated Hsp90 K63 ubiquitination from the present study.** In wild-type CM cells, K63-ubiquitinated Hsp90 (red) is localized to the cytosol. Hsp90 secretion is properly regulated in CM of wild-type embryos, resulting in normal behavior of the CM and possibly normal expansion of the CM required for neural fold elevation. In *Hectd1* mutant CM cells, the lack of K63 ubiquitination of Hsp90 results in an increased pool of Hsp90 targeted for secretion and localized to the membrane (red). Excess secretion of Hsp90 leads to abnormal behavior of the CM, potentially contributing to failure of CM expansion, neural fold elevation, and neural tube closure.

function of Hsp90 itself. Accordingly, our data demonstrate that Hectd1-dependent K63-Ub<sub>n</sub> of Hsp90 controls its intracellular localization and secretion.

### Hectd1-dependent ubiquitination of Hsp90 regulates its secretion

Little is known about the pathways regulating secretion of Hsp90. Phosphorylation of Hsp90 $\alpha$  by PKA on Thr90 promotes its secretion (Wang et al., 2009). Furthermore, the four C-terminal amino acid residues of Hsp90 $\alpha$  (EEVD) are critical for regulation of its secretion (Wang et al., 2009). This domain provides a point of interaction for tetratricopeptide repeat (TPR) domain-containing proteins preventing secretion by docking Hsp90 $\alpha$  in the cytoplasm (Wang et al., 2009). Similarly, our data demonstrate that Hectd1 is a negative regulator of Hsp90 $\alpha$  secretion. In contrast to the interaction of Hsp90 $\alpha$  with TPR domain-containing proteins, our binding data demonstrate that Hectd1 interacts with Hsp90 $\alpha$  through a region located between amino acids 241 and 617. It's important

to note that it is not simply the interaction of Hectd1 with Hsp90 $\alpha$  that prevents its secretion; the Ub ligase activity of Hectd1 is also required. K63-linked Ub regulates trafficking of proteins in numerous systems (Mukhopadhyay and Riezman, 2007). It remains to be determined how Hectd1-dependent ubiquitination of Hsp90 $\alpha$  prevents its secretion. One clue comes from our finding that a Hectd1-dependent 30-kD Ub protein coimmunoprecipitates with Hsp90 $\alpha$  under highly denaturing conditions. This could either represent a tightly associated protein or a cleavage product of Hsp90 $\alpha$ . It is possible that association of Hsp90 $\alpha$  with this 30-kD Ub protein prevents membrane translocation. Alternatively, Hectd1-dependent K63-Ub $n$  of Hsp90 $\alpha$  may lead to cleavage of Hsp90 $\alpha$  to a fragment that cannot be secreted. Precisely how Hectd1-dependent ubiquitination regulates Hsp90 secretion remains to be determined.

### Hectd1-dependent ubiquitination of Hsp90 regulates CM cell behavior

Our data support the model that abnormal behavior of CM cells is mediated by increased secretion of Hsp90 $\alpha$  in mutant cells (Fig. 7). Increased extracellular Hsp90 $\alpha$  is sufficient to induce increased emigration from CM explants. Additionally, emigration and migration of cells from *Hectd1* mutant CM explants is highly dependent on secretion of Hsp90 $\alpha$ . How might abnormal behavior of the CM result in failure of neural fold elevation? Current models of cranial neural tube closure predict that a driving force for cranial neural fold elevation is the expansion of the extracellular matrix, displacing CM cells and resulting in expansion of the space between cells (Morris and Solursh, 1978a,b; Schoenwolf and Fisher, 1983; Morris-Wiman and Brinkley, 1990a,b,c; Copp, 2005). Our data demonstrate that the abnormal behavior of *Hectd1* mutant CM is related to the excess secretion of Hsp90. We propose that the abnormal behavior of the CM in *Hectd1* mutants interferes with the expansion of the CM that occurs as the extracellular matrix expands, resulting in the dense CM found in *Hectd1* mutants. The substrates of extracellular Hsp90 include cell surface receptors and extracellular matrix components and likely a host of other client proteins, which can regulate cell behavior (Tsutsumi and Neckers, 2007; Li et al., 2012; Sims et al., 2011). Thus, excess extracellular Hsp90 in the CM may influence expansion of the extracellular matrix, interaction of CM cells with the extracellular matrix, and/or motility of the CM cells. Our previous observation that the increased density of CM in *Hectd1* mutants was not associated with alterations in cell proliferation and apoptosis (Zohn et al., 2007) supports the hypothesis that increased CM density is caused by effects on cell rearrangements. Whether this abnormal cellular behavior is truly responsible for the failed CM expansion and neural tube closure in *Hectd1* mutants still remains to be determined. It is important to note that Hectd1 likely has multiple substrates, as demonstrated from our proteomic screens, and it is possible that these also contribute to the abnormal CM behavior and NTDs in *Hectd1* mutants. In conclusion, our study establishes a novel Ub ligase–substrate interaction in vivo between Hectd1 and Hsp90 $\alpha$  and provides a molecular mechanism for the abnormal migratory behavior of the CM in *Hectd1* mutants.

## Materials and methods

### Mice genotyping and cell culture

*Hectd1<sup>opm</sup>* and *Hectd1<sup>NC</sup>* (*Hectd1<sup>X</sup>*) mouse lines have been described previously (Fig. 2 A; Kasarskis et al., 1998; Zohn et al., 2007). *Hectd1<sup>opm</sup>* represents an *N*-ethyl-*N*-nitrosourea (ENU)-induced allele, resulting in truncation of the Hectd1 protein at amino acid 144. *Hectd1<sup>X</sup>* results from a gene trap insertion into the HECT domain. *Hectd1<sup>opm</sup>* and *Hectd1<sup>X</sup>* were genotyped using amplification refractory mutation system PCR (ARMS-PCR; Ye et al., 2001) and gap PCR (Bandyopadhyay et al., 2004), respectively, and as shown (Fig. S3). For ARMS-PCR to genotype *Hectd1<sup>opm</sup>*, the primers used were: forward inner primer (A allele), 5'-AGGGGCAGTCTTGAGGCTGGTGGATA-3'; reverse inner primer (T allele), 5'-TGTACGAATGAAGGTNAGAACACAATACA-3'; forward outer primer, 5'-ACCTTGTGTCCTCTGTAGGTGCTGGA-3'; and reverse outer primer, 5'-GCTCCATTITGCCACAGAGTCTCGATAC-3'. Mice carrying the *Hectd1<sup>X</sup>* gene trap allele were genotyped using gap PCR. The primers used were 52860334F, 5'-CACTGAAAGTGACGGGGCTTGGAAC-3'; 52859614R, 5'-ATAATAATAAAGCACTTAACATATCCCGAG-3'; and B-Gal-Rev1, 5'-GACAGTATCGGCCTCAGGAAGATCG-3'. CM cultures were prepared according to a standard protocol for isolating mouse embryonic fibroblasts (MEFs) from E12.5 mouse embryo heads (Nagy et al., 2003). HEK293T and CM cells were cultured in DME (Invitrogen), supplemented with 10% FCS, 100 IU/ml penicillin G, and 100  $\mu$ g/ml streptomycin sulfate (Invitrogen). Bright field images for whole embryos were obtained using a microscope (Discover V8; Carl Zeiss) using an Achromat S FWD 107 mm lens with a magnification of 0.63 $\times$ . Images were captured using a camera (AxioCam ERc 5s; Carl Zeiss) and processed with Photoshop (8.0) and Illustrator (10.0; both from Adobe).

### Mammalian expression constructs

pGKKT-Hectd1<sup>ANK</sup>, pCMV-HA-Hectd1<sup>ANK</sup>, pCMV-HA-Hectd1, and pCMV-HA-Hectd1\* were assembled by ligation of RT-PCR generated fragments and ESTs encoding fragments of mouse Hectd1 (Fig. 2). pCMV-Sport6-Hsp90aa1 expression plasmid was obtained from Invitrogen (Clone ID no. 6491307) and subcloned into pCMV-Myc (Takara Bio Inc.). EGFP-C1-UbKO was obtained from Addgene (Addgene plasmid 11934; Bergink et al., 2006). pCMV-FLAG-Ub, pCMV-FLAG-K63R-Ub, and pCMV-FLAG-K48R-Ub were provided by Drs. H. McLauchlan and P. Cohen (University of Dundee, Dundee, Scotland, UK; Windheim et al., 2008). Control, scrambled, and custom Hectd1 (5'-AGATAAAGGTGGTATATA-3') siRNA were purchased from Thermo Fisher Scientific. The effectiveness of the Hectd1 siRNA was demonstrated by transfection of HEK293T cells with control, scrambled, and Hectd1 constructs followed by Western blotting to detect Hectd1 (Fig. S4).

### Proteomic screens

The Matchmaker Two-Hybrid System 3 was used according to manufacturer's instructions to screen the Matchmaker Pretransformed E11.5 mouse cDNA library (Takara Bio Inc.) for proteins that bind to Hectd1<sup>ANK</sup>. For the LC-MS screen, Hectd1 was immunoprecipitated in immunoprecipitation buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 150 mM NaCl, and 0.1% Triton X-100 with protease inhibitor cocktail) from lysates of wild-type E10.5 mouse; embryo heads were resolved on 3–8% Tris-acetate denaturing gels (Invitrogen) and processed (Jensen et al., 1999; Cargile et al., 2004; Essader et al., 2005). Peptide sequences were searched against the mouse Uniprot protein database (<http://www.uniprot.org/>) using the Sequest algorithm in the Bioworks Browser software package (Thermo Fisher Scientific).

### Antibodies and immunofluorescence assay

Anti-peptide Hectd1 rabbit polyclonal antibody was generated (Biosynthesis Inc.) against mouse Hectd1 amino acids 487–505 (CPVNKGDD-KKKDTNKDEE) and used for all experiments unless otherwise indicated. The specificity of the Hectd1 antibody was confirmed in an immunoblotting assay (Fig. S1). Serum from rabbits immunized with Hectd1 peptide was used for Western blot analysis or affinity purified using the RAP Affinity Purification kit (Invitrogen) for immunoprecipitation. For enrichment of Ub proteins that bind to Rad23, the ubiquitinated protein enrichment kit (EMD) was used according to the manufacturer's instructions. Other antibodies used were: HSP90 (E289) antibody (4875; Cell Signaling Technology), anti-Hsp90 mouse monoclonal antibody (mAb; EMD-17D7, CA1023; EMD), HSP90 $\alpha$  (ADI-SPS-771; Enzo Life Sciences), mAb to mono- and polyubiquitylated protein conjugates FK2H (BML-PW0150; Enzo Life Sciences), FK1 mAb to polyubiquitylated

conjugates (BML-PW8805; Enzo Life Sciences), Hsp90 $\beta$  (RB-118-PO; Thermo Fisher Scientific), HECTD1 mAb clone 1E10 (H00025831-M03; Abnova), c-Myc mAb (631206; Takara Bio Inc.), polyclonal Myc-Tag antibody (2272; Cell Signaling Technology), HA-Tag polyclonal antibody (631207; Takara Bio Inc.), HA mAb clone 16B12 (MMS-101R; Covance), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 14C10), rabbit mAb (14C10; Cell Signaling Technology), anti-FLAG monoclonal (M2) antibody (F1804; Sigma-Aldrich), anti-actin mAb clone C4 (MAB1501R; Millipore), rabbit anti-GFP (A-11122; Invitrogen), goat anti-rabbit IgG (H+L)-HRP conjugate (1721019; Bio-Rad Laboratories), goat anti-mouse IgG (H+L)-HRP conjugate (1721011; Bio-Rad Laboratories), rabbit anti-goat IgG (H&L)-HRP conjugate (ab6741; Abcam), Hoechst 33342 (P5541; Promega), lysine 48 linkage-specific polyubiquitin (Ub $\alpha$ ) antibody (4289; Cell Signaling Technology), Ub $\alpha$  (K63 linkage-specific) mAb (HWA4C4, BML-PW0600; Enzo Life Sciences), Alexa Fluor 555 goat anti-rat IgG (H+L; A21434; Invitrogen), Alexa Fluor 555 goat anti-rabbit IgG (H+L; A21429; Invitrogen), Alexa Fluor 488 goat anti-rabbit IgG (H+L; A11034, Invitrogen), Alexa Fluor 488 goat anti-mouse IgG (H+L; A11029; Invitrogen), and Alexa Fluor 546 donkey anti-goat IgG (H+L; A11056; Invitrogen). Because of the high homology between Hsp90 family members, we confirmed antibody specificity against Hsp90 $\alpha$  and - $\beta$  in transfected HEK293T lysates. Our results demonstrate that the Hsp90 antibody (no. 4877; Cell Signaling Technology) recognizes both  $\alpha$  and  $\beta$  subtypes, whereas the Hsp90 $\alpha$  (no. SPS-771; Enzo Life Sciences) uniquely recognizes Hsp90 $\alpha$ . We did not identify an antibody that uniquely recognizes Hsp90 $\beta$ . To detect extracellular Hsp90 $\alpha$ , live cells were treated with anti-Hsp90 $\alpha$  antibody without permeabilization with Triton X-100 for 3 h at 37°C before fixation. In contrast, all other immunofluorescence experiments were performed as described previously (Zohn et al., 2006). In brief, cells were fixed for 20 min in 4% paraformaldehyde, washed in PBS, and permeabilized in PBS + 0.1% Triton X-100. Primary antibody incubations were performed overnight and secondary antibody incubations were performed for 20 min. Immunofluorescence images were obtained at 25°C with a fluoromount mounting medium (Sigma-Aldrich) using a confocal microscope (LSM-510; Carl Zeiss) with the 63 $\times$  objective lens (Plan-Apochromat NA 1.4 oil, differential interference contrast). Digital images were acquired using AxioVision LE software (Carl Zeiss) and processed with Photoshop (8.0) and Illustrator (10.0).

#### Co-immunoprecipitation, ubiquitination assays, and ELISA

For *in vitro* binding assays, biotinylated peptides were synthesized using the TNT T7 Coupled Reticulocyte Lysate system and Transcend tRNA (Promega). Binding assays were performed on precleared lysates at 25°C for 1 h using the Matchmaker Co-IP kit (Takara Bio Inc.) and Western blots developed using the Transcend Chemiluminescent Non-Radioactive Translation Detection system (Promega). Binding assays in HEK293T cells were performed at 4°C for 18 h as described previously (Zohn et al., 2006). For lenient binding conditions, a mild immunoprecipitation buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 150 mM NaCl, and 0.1% Triton X-100 with protease inhibitor cocktail) was used, and for stringent binding conditions, radioimmunoprecipitation assay buffer (no. 89901; Thermo Fisher Scientific) with protease inhibition cocktail (Roche) was used. For ubiquitination assays in HEK293T cells, 44 h after transfection, cells were treated with the proteasome inhibitor MG132 (20  $\mu$ M; Sigma-Aldrich) for 4 h, washed in ice-cold PBS, and lysed in ubiquitination lysis buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.1% Triton X-100, complete protease inhibitor cocktail, 100  $\mu$ M MG132, 20  $\mu$ M Ub aldehyde, and 100  $\mu$ M *N*-ethylmaleimide). Images of Western blot gels were acquired with a ChemiDoc XRS system (Bio-Rad Laboratories) and Quality One (4.6.3) software or using the Odyssey infrared imaging system (LI-COR Biosciences) and processed with Photoshop (8.0) and Illustrator (10.0). Scanned films were quantified using ImageJ software (<http://rsb.info.nih.gov/ij/>). To quantify ubiquitination assays, the whole lane from the well to the bottom of the gel was used for quantification. Statistically significant differences were assessed by a paired two-tailed Student's *t* test. All statistical analyses were performed using MS Excel software (Microsoft). Differences were considered to be significant for values of  $P < 0.05$ .

#### Cell shape assay

10 embryos each of wild type and *Hecht1* mutant at E9.5 were fixed and stained using the hematoxylin and eosin method as described previously (Zohn et al., 2007). Bright field images were acquired using a microscope (BX61; Olympus) at 10 $\times$  and 40 $\times$  magnification, with objective

lenses of NA 0.4 and 0.85, respectively. Images were taken using a DP71 camera (Olympus). Digital images were acquired using DPController and DPManager software (Olympus) and processed with Photoshop (8.0) and Illustrator (10.0). Cells were imaged using bright field microscopy at 100 $\times$  magnification. Cell perimeters ( $n = 130$ ) were computed using NeuronJ (<http://www.imagescience.org/meijering/software/neuronj/>), and cell areas ( $n = 130$ ) were computed using ImageJ (<http://rsbweb.nih.gov/ij/>). Cell shape was defined using the equation  $(4\pi \times \text{cell area}/\text{cell perimeter}^2)$ , where  $>1$  indicates a perfect circle and values  $<1$  indicate a more irregular shape.

#### Cell migration assays and quantification

For explant migration assays, E8.5 *Hecht1*<sup>WT</sup> and *Hecht1*<sup>0</sup> embryos were collected and washed in 1x PBS, and explants were microdissected from the CM, taking care to remove the neural epithelium and surface ectoderm. Explants were cultured for 24 h on fibronectin-coated glass coverslips in DME containing 10% FBS with or without 25  $\mu$ g/ml anti-Hsp90 $\alpha$  antibody as described previously (Sidera et al., 2008). Explants were photographed using a microscope (CKX41; Olympus) with the 40 $\times$ /NA 0.55 objective lens. Images were captured using a DP70 camera (Olympus) and processed with Photoshop (8.0) and Illustrator (10.0). The mean migratory distance from the circumference of the explant to the migratory front and the mean cell number in unit area (200  $\mu$ m $^2$ ) perpendicular and mid-distant between the migratory front and explant circumference (dotted lines) were quantitated. Results are expressed as the mean migratory distance (in micrometers) of 50 randomly chosen cells at the migrating front and the mean number of migrating cells in 10 randomly chosen squares of unit area (200  $\mu$ m $^2$ ) at a mid-distance between the explant circumference and the migrating front, perpendicular to the explant circumference. Inhibition of secretory mechanisms was achieved by treatment of explants for 16 h in 200  $\mu$ M DMA, whereas control explants were treated with DMSO vehicle. Statistical significance of differences of means was tested with a paired two-tailed Student's *t* test.

#### Online supplemental material

Fig. S1 shows the specificity of the anti-Hecht1 antibody used in this study. Fig. S2 shows colocalization of Hecht1 and Hsp90 in HEK293T cells. Fig. S3 shows the genotyping strategy to identify *Hecht1*<sup>0pm</sup> and *Hecht1*<sup>1X</sup>. Fig. S4 shows the effectiveness of the siRNA targeting Hecht1 in reducing protein expression when transfected in HEK293T cells. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201105101/DC1>.

The authors would like to express their appreciation to Drs. Joshua Corbin, Jyoti Jaiswal, Judy Liu, and Vittorio Gallo for helpful discussions and critical reading of the manuscript, and Samer Nuwayhid for technical assistance. We are grateful to Dr. Lee Niswander for support in the early days of this project, members of the Dr. Mary Baylies laboratory for help with the yeast two-hybrid screen, members of the Center for Neuroscience Research for helpful suggestions, Drs Kristy Brown and Yetrib Hathout for help with MS instrumentation and data analysis, and Dr. Anastas Popratiloff, director of the Center for Microscopy and Image Analysis at the George Washington University, for help with confocal microscopy.

This work was partially supported by National Institutes of Health grant IDRC P30HD40677 (to Y. Hathout and A. Popratiloff) and a Basil O'Conner Award from the March of Dimes, a Young Investigator Award from the Spina Bifida Association, and grant NICHD-R01-HD058629 (from the National Institute of Child Health and Human Development) to I.E. Zohn.

Submitted: 19 May 2011

Accepted: 13 February 2012

#### References

- Bandyopadhyay, A., S. Bandyopadhyay, J. Basak, B.C. Mondal, A.A. Sarkar, S. Majumdar, M.K. Das, S. Chandra, A. Mukhopadhyay, M. Sanghamitra, et al. 2004. Profile of beta-thalassemia in eastern India and its prenatal diagnosis. *Prenat. Diagn.* 24:992–996. <http://dx.doi.org/10.1002/pd.1049>
- Bergink, S., F.A. Salomons, D. Hoogstraten, T.A. Grootenhuis, H. de Waard, J. Wu, L. Yuan, E. Citterio, A.B. Houtsma, J. Neefjes, et al. 2006. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. *Genes Dev.* 20:1343–1352. <http://dx.doi.org/10.1101/gad.373706>
- Bonifacino, J.S., and L.M. Traub. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. *Annu. Rev. Biochem.* 72:395–447. <http://dx.doi.org/10.1146/annurev.biochem.72.121801.161800>

Cargile, B.J., and J.L. Stephenson Jr. 2004. An alternative to tandem mass spectrometry: isoelectric point and accurate mass for the identification of peptides. *Anal. Chem.* 76:267–275. <http://dx.doi.org/10.1021/ac0352070>

Chen, Z.F., and R.R. Behringer. 1995. twist is required in head mesenchyme for cranial neural tube morphogenesis. *Genes Dev.* 9:686–699. <http://dx.doi.org/10.1101/gad.9.6.686>

Chen, L., and K. Madura. 2002. Rad23 promotes the targeting of proteolytic substrates to the proteasome. *Mol. Cell. Biol.* 22:4902–4913. <http://dx.doi.org/10.1128/MCB.22.13.4902-4913.2002>

Cheng, C.F., J. Fan, M. Fedesco, S. Guan, Y. Li, B. Bandyopadhyay, A.M. Bright, D. Yerushalmi, M. Liang, M. Chen, et al. 2008. Transforming growth factor alpha (TGF $\alpha$ )-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGF $\beta$ -rich environment during wound healing. *Mol. Cell. Biol.* 28:3344–3358. <http://dx.doi.org/10.1128/MCB.01287-07>

Clayton, A., A. Turkes, H. Navabi, M.D. Mason, and Z. Tabi. 2005. Induction of heat shock proteins in B-cell exosomes. *J. Cell Sci.* 118:3631–3638. <http://dx.doi.org/10.1242/jcs.02494>

Copp, A.J. 2005. Neurulation in the cranial region—normal and abnormal. *J. Anat.* 207:623–635. <http://dx.doi.org/10.1111/j.1469-7580.2005.00476.x>

Copp, A.J., N.D. Greene, and J.N. Murdoch. 2003. The genetic basis of mammalian neurulation. *Nat. Rev. Genet.* 4:784–793. <http://dx.doi.org/10.1038/nrg1181>

Essader, A.S., B.J. Cargile, J.L. Bundy, and J.L. Stephenson Jr. 2005. A comparison of immobilized pH gradient isoelectric focusing and strong-cation-exchange chromatography as a first dimension in shotgun proteomics. *Proteomics.* 5:24–34. <http://dx.doi.org/10.1002/pmic.200400888>

Eustace, B.K., and D.G. Jay. 2004. Extracellular roles for the molecular chaperone, hsp90. *Cell Cycle.* 3:1098–1100. <http://dx.doi.org/10.4161/cc.3.9.1088>

Hartmann-Petersen, R., and C. Gordon. 2004. Protein degradation: recognition of ubiquitinylated substrates. *Curr. Biol.* 14:R754–R756. <http://dx.doi.org/10.1016/j.cub.2004.09.012>

Hegmans, J.P., M.P. Bard, A. Hemmes, T.M. Luider, M.J. Kleijmeer, J.B. Prins, L. Zitvogel, S.A. Burgers, H.C. Hoogsteen, and B.N. Lambrecht. 2004. Proteomic analysis of exosomes secreted by human mesothelioma cells. *Am. J. Pathol.* 164:1807–1815. [http://dx.doi.org/10.1016/S0002-9440\(10\)63739-X](http://dx.doi.org/10.1016/S0002-9440(10)63739-X)

Jensen, O.N., M. Wilm, A. Shevchenko, and M. Mann. 1999. Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. *Methods Mol. Biol.* 112:513–530.

Kasarskis, A., K. Manova, and K.V. Anderson. 1998. A phenotype-based screen for embryonic lethal mutations in the mouse. *Proc. Natl. Acad. Sci. USA.* 95:7485–7490. <http://dx.doi.org/10.1073/pnas.95.13.7485>

Li, W., Y. Li, S. Guan, J. Fan, C.F. Cheng, A.M. Bright, C. Chinn, M. Chen, and D.T. Woodley. 2007. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. *EMBO J.* 26:1221–1233. <http://dx.doi.org/10.1038/sj.emboj.7601579>

Li, W., D. Sahu, and F. Tsen. 2012. Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. *Biochim. Biophys. Acta.* 1823:730–741. <http://dx.doi.org/10.1016/j.bbamcr.2011.09.009>

Liao, D.F., Z.G. Jin, A.S. Baas, G. Daum, S.P. Gygi, R. Aebersold, and B.C. Berk. 2000. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. *J. Biol. Chem.* 275:189–196. <http://dx.doi.org/10.1074/jbc.275.1.189>

McCreedy, J., J.D. Sims, D. Chan, and D.G. Jay. 2010. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. *BMC Cancer.* 10:294. <http://dx.doi.org/10.1186/1471-2407-10-294>

McDonough, H., and C. Patterson. 2003. CHIP: a link between the chaperone and proteasome systems. *Cell Stress Chaperones.* 8:303–308. [http://dx.doi.org/10.1379/1466-1268\(2003\)008<0303:CALBTC>2.0.CO;2](http://dx.doi.org/10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2)

Morris-Wiman, J., and L.L. Brinkley. 1990a. Changes in mesenchymal cell and hyaluronate distribution correlate with *in vivo* elevation of the mouse mesencephalic neural folds. *Anat. Rec.* 226:383–395. <http://dx.doi.org/10.1002/ar.1092260316>

Morris-Wiman, J., and L.L. Brinkley. 1990b. The role of the mesenchyme in mouse neural fold elevation. I. Patterns of mesenchymal cell distribution and proliferation in embryos developing *in vitro*. *Am. J. Anat.* 188:121–132. <http://dx.doi.org/10.1002/ajia.1001880203>

Morris-Wiman, J., and L.L. Brinkley. 1990c. The role of the mesenchyme in mouse neural fold elevation. II. Patterns of hyaluronate synthesis and distribution in embryos developing *in vitro*. *Am. J. Anat.* 188:133–147. <http://dx.doi.org/10.1002/ajia.1001880204>

Morris, G.M., and M. Solursh. 1978a. Regional differences in mesenchymal cell morphology and glycosaminoglycans in early neural-fold stage rat embryos. *J. Embryol. Exp. Morphol.* 46:37–52.

Morris, G.M., and M. Solursh. 1978b. The role of primary mesenchyme in normal and abnormal morphogenesis of mammalian neural folds. *Zool.* 6:33–38.

Morris-Kay, G.M., F. Tuckett, and M. Solursh. 1986. The effects of *Streptomyces* hyaluronidase on tissue organization and cell cycle time in rat embryos. *J. Embryol. Exp. Morphol.* 98:59–70.

Mukhopadhyay, D., and H. Riezman. 2007. Proteasome-independent functions of ubiquitin in endocytosis and signaling. *Science.* 315:201–205. <http://dx.doi.org/10.1126/science.1127085>

Murata, S., T. Chiba, and K. Tanaka. 2003. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. *Int. J. Biochem. Cell Biol.* 35:572–578. [http://dx.doi.org/10.1016/S1357-2725\(02\)00394-1](http://dx.doi.org/10.1016/S1357-2725(02)00394-1)

Nagy, A., M. Gertsenstein, K. Vintersten, and R.R. Behringer. 2003. Manipulating the Mouse Embryo: A Laboratory Manual. Chapter 8, protocol 1. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 371–375..

Pickart, C.M. 2001. Mechanisms underlying ubiquitination. *Annu. Rev. Biochem.* 70:503–533. <http://dx.doi.org/10.1146/annurev.biochem.70.1.503>

Schoenwolf, G.C., and M. Fisher. 1983. Analysis of the effects of *Streptomyces* hyaluronidase on formation of the neural tube. *J. Embryol. Exp. Morphol.* 73:1–15.

Sidera, K., M. Gaitanou, D. Stellas, R. Matsas, and E. Patsavoudi. 2008. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. *J. Biol. Chem.* 283:2031–2041. <http://dx.doi.org/10.1074/jbc.M701803200>

Sims, J.D., J. McCready, and D.G. Jay. 2011. Extracellular heat shock protein (Hsp)70 and Hsp90 $\alpha$  assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. *PLoS ONE.* 6:e18848. <http://dx.doi.org/10.1371/journal.pone.0018848>

Tsutsumi, S., and L. Neckers. 2007. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. *Cancer Sci.* 98:1536–1539. <http://dx.doi.org/10.1111/j.1349-7006.2007.00561.x>

Tuckett, F., and G.M. Morris-Kay. 1986. The distribution of fibronectin, laminin and entactin in the neurulating rat embryo studied by indirect immunofluorescence. *J. Embryol. Exp. Morphol.* 94:95–112.

Urbé, S. 2005. Ubiquitin and endocytic protein sorting. *Essays Biochem.* 41:81–98. <http://dx.doi.org/10.1042/EB0410081>

Verschueren, P., Y. Croes, P.R. van den IJssel, R.A. Quinlan, W.W. de Jong, and W.C. Boelens. 2002. Translocation of small heat shock proteins to the actin cytoskeleton upon proteasomal inhibition. *J. Mol. Cell. Cardiol.* 34:1117–1128. <http://dx.doi.org/10.1006/jmcc.2001.1493>

Wang, X., X. Song, W. Zhuo, Y. Fu, H. Shi, Y. Liang, M. Tong, G. Chang, and Y. Luo. 2009. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. *Proc. Natl. Acad. Sci. USA.* 106:21288–21293. <http://dx.doi.org/10.1073/pnas.0908151106>

Windheim, M., M. Stafford, M. Peggie, and P. Cohen. 2008. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of I $\kappa$ B kinase. *Mol. Cell. Biol.* 28:1783–1791. <http://dx.doi.org/10.1128/MCB.02380-06>

Ye, S., S. Dhillon, X. Ke, A.R. Collins, and I.N. Day. 2001. An efficient procedure for genotyping single nucleotide polymorphisms. *Nucleic Acids Res.* 29:E88. <http://dx.doi.org/10.1093/nar/29.17.e88>

Zohn, I.E., and A.A. Sarkar. 2008. Modeling neural tube defects in the mouse. *Curr. Top. Dev. Biol.* 84:1–35. [http://dx.doi.org/10.1016/S0070-2153\(08\)00601-7](http://dx.doi.org/10.1016/S0070-2153(08)00601-7)

Zohn, I.E., Y. Li, E.Y. Skolnik, K.V. Anderson, J. Han, and L. Niswander. 2006. p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. *Cell.* 125:957–969. <http://dx.doi.org/10.1016/j.cell.2006.03.048>

Zohn, I.E., Y. Li, K.V. Anderson, and L. Niswander. 2007. The Hectd1 ubiquitin ligase is required for development of the head mesenchyme and neural tube closure. *Dev. Biol.* 306:208–221. <http://dx.doi.org/10.1016/j.ydbio.2007.03.018>